Postoperative Nausea and Vomiting
Conditions
Interventions
Control group:One milliliter of normal saline was intravenously injected 15 minutes before the end of surgery. Postoperatively, a patient - controlled intravenous analgesia (PCIA) pump was used, with
Single - dose group:Six point two five milligrams (1 mL) of promethazine injection was intravenously injected 15 minutes before the end of surgery. Postoperatively, a patient-controlled intravenous an
Combination group:Six point two five milligrams (1 mL) of promethazine injection was intravenously injected 15 minutes before the end of surgery. Postoperatively, a patient-controlled intravenous anal
Sponsors
Affiliated Stomatology Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
Female
Age
12 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age: 12–65 years old; 2.American Society of Anesthesiologists (ASA) physical status classification: Class 1–2; 3.Body Mass Index (BMI): 18.5–23.9 kg/m^2; 4.Definitive diagnosis of temporomandibular joint disorder (Wilkes Stage IV) and scheduled for temporomandibular joint disc reduction and fixation surgery under general anesthesia, with the operation time less than 3 hours.
Exclusion criteria
Exclusion criteria: 1.Allergy to the investigational drug. 2.Pregnant or lactating females. 3.Patients complicated with glaucoma, benign prostatic hyperplasia, epilepsy, or myasthenia gravis. 4.Patients with hepatic and renal insufficiency. 5.Patients with prolonged QT interval. 6.Those who have used antiemetic drugs within 48 hours before surgery. 7.History of alcohol or opioid substance abuse. 8.Preoperative coma, psychiatric symptoms or intellectual disability; or combined with underlying diseases such as cardiovascular diseases and diabetes mellitus. 9.Long-term smoking history (smoking >=10 cigarettes per day for more than 1 consecutive year). 10.Severe malformation or perforation of the articular disc, or severe destruction of anatomical structure that renders temporomandibular joint disc repositioning and fixation surgery unfeasible. 11.Participation in other clinical trials concurrently during the study intervention period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of postoperative nausea and vomiting ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Nausea Severity Score ;Vomiting/Retching Episode Frequency Score;Postoperative Nausea and Vomiting Impact Scale Score;PONV Remission Rate;Postoperative Surgical Site Pain Score;Postoperative Rescue Antiemetic Usage;Administration status of postoperative rescue analgesics;Anesthetic emergence time;Adverse event occurrence;PACU stay time;Postoperative Ramsay Sedation Score;Postoperative basic vital signs;Surgical duration;Intraoperative anesthetic dosage;Intraoperative fluid volume;Intraoperative blood loss; | — |
Countries
China
Contacts
Public ContactQin Zhaojun
Affiliated Stomatology Hospital of Guangzhou Medical University
Outcome results
None listed